Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

C-reactive protein and echocardiography have little impact on risk stratification in never-treated hypertensive patients

Journal of Human Hypertension volume 20, pages 587–592 (2006)Cite this article

Abstract

The aim of this study was to assess the contribution of increased concentrations of high-sensitivity C-reactive protein (hsCRP) and echocardiography to risk stratification according to the 2003 European guidelines for the management of arterial hypertension in patients with untreated hypertension. A total of 207 consecutive medical outpatients with untreated hypertension were included. History and clinical examination, electrocardiography, laboratory analyses including the measurement of hsCRP and echocardiography were performed in all patients. Patients were classified into four risk groups with and without using echocardiography and hsCRP concentrations of at least 10 mg/l according to the 2003 guidelines for the management of hypertension. The majority of the 207 patients (81%) were at moderate or high cardiovascular risk before adding echocardiography and/or hsCRP to the risk stratification process. When echocardiography was included, only three patients were reclassified from the moderate added risk to the high added risk group. Adding hsCRP concentrations of at least 10 mg/l had no impact on risk stratification. Using an hsCRP cutoff level of 3 mg/l, one patient was at moderate instead of low added risk, eight patients were at high instead of moderate added risk and one patient was at very high instead of high added risk. We conclude that hsCRP at the proposed cutoff level of 10 mg/l has no impact on risk stratification in outpatients with untreated hypertension. An hsCRP cutoff level of 3 mg/l may be more suitable for risk stratification. Finally, our data suggest that depending on the population studied, there is minimal impact of echocardiography on risk stratification.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ . Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–1360.

    Article  PubMed  Google Scholar 

  2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.

    Article  CAS  PubMed  Google Scholar 

  3. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761–767.

    Article  CAS  PubMed  Google Scholar 

  4. Cullen P, Schulte H, Assmann G . The Munster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 1997; 96: 2128–2136.

    Article  CAS  PubMed  Google Scholar 

  5. Anderson KM, Wilson PW, Odell PM, Kannel WB . An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356–362.

    Article  CAS  PubMed  Google Scholar 

  6. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.

    Article  CAS  PubMed  Google Scholar 

  7. 1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151–183.

  8. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  9. Schillaci G, de Simone G, Reboldi G, Porcellati C, Devereux RB, Verdecchia P . Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens 2002; 20: 1519–1525.

    Article  CAS  PubMed  Google Scholar 

  10. Cuspidi C, Michev L, Severgnini B, Meani S, Fusi V, Valerio C et al. Change in cardiovascular risk profile by echocardiography in medium-risk elderly hypertensives. J Hum Hypertens 2003; 17: 101–106.

    Article  CAS  PubMed  Google Scholar 

  11. Cuspidi C, Lonati L, Macca G, Sampieri L, Fusi V, Severgnini B et al. Cardiovascular risk stratification in hypertensive patients: impact of echocardiography and carotid ultrasonography. J Hypertens 2001; 19: 375–380.

    Article  CAS  PubMed  Google Scholar 

  12. Martinez MA, Sancho T, Armada E, Rubio JM, Anton JL, Torre A et al. Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. Am J Hypertens 2003; 16: 556–563.

    Article  PubMed  Google Scholar 

  13. Luque M, de Rivas B, Alvarez B, Garcia G, Fernandez C, Martell N . Influence of target organ lesion detection (assessment of microalbuminuria and echocardiogram) in cardiovascular risk stratification and treatment of untreated hypertensive patients. J Hum Hypertens 2006; 20: 187–192.

    Article  CAS  PubMed  Google Scholar 

  14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979.

    Article  CAS  PubMed  Google Scholar 

  15. Ridker PM, Buring JE, Cook NR, Rifai N . C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391–397.

    Article  PubMed  Google Scholar 

  16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511.

    Article  PubMed  Google Scholar 

  17. Palmieri V, Dahlof B, DeQuattro V, Sharpe N, Bella JN, de Simone G et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34: 1625–1632.

    Article  CAS  PubMed  Google Scholar 

  18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.

    Article  CAS  PubMed  Google Scholar 

  19. Ridker PM, Cook N . Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955–1959.

    Article  PubMed  Google Scholar 

  20. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, de Jong PE, Gans RO et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004; 43: 791–796.

    Article  CAS  PubMed  Google Scholar 

  21. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–1965.

    Article  CAS  PubMed  Google Scholar 

  22. Conen D, Zeller A, Pfisterer M, Martina B . Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 2006; 97: 249–252.

    Article  CAS  PubMed  Google Scholar 

  23. Leoncini G, Sacchi G, Ravera M, Viazzi F, Ratto E, Vettoretti S et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002; 16: 399–404.

    Article  CAS  PubMed  Google Scholar 

  24. Leoncini G, Sacchi G, Viazzi F, Ravera M, Parodi D, Ratto E et al. Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J Hypertens 2002; 20: 1315–1321.

    Article  CAS  PubMed  Google Scholar 

  25. Tsioufis C, Dimitriadis K, Antoniadis D, Stefanadis C, Kallikazaros I . Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens 2004; 17: 470–476.

    Article  CAS  PubMed  Google Scholar 

  26. Ferrara LA, Vaccaro O, Cardoni O, Laurenzi M, Mancini M, Zanchetti A . Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens 2005; 18: 1282–1287.

    Article  PubMed  Google Scholar 

  27. Wong ND, Pio J, Valencia R, Thakal G . Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Prev Cardiol 2001; 4: 109–114.

    Article  CAS  PubMed  Google Scholar 

  28. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24: 1509–1515.

    Article  CAS  PubMed  Google Scholar 

  29. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino Jr RB, Herrington DM . The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005; 46: 1869–1874.

    Article  CAS  PubMed  Google Scholar 

  30. Xie X, Liu K, Stamler J, Stamler R . Ethnic differences in electrocardiographic left ventricular hypertrophy in young and middle-aged employed American men. Am J Cardiol 1994; 73: 564–567.

    Article  CAS  PubMed  Google Scholar 

  31. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005; 46: 124–129.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by unrestricted grant from Bayer Pharma, Zürich, Switzerland and from the University Hospital Basel, Switzerland.

Author information

Authors and Affiliations

  1. Department of Cardiology, University Hospital Basel, Basel, Switzerland

    D Conen & T Dieterle

  2. Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland

    A Zeller & B Martina

Authors
  1. D Conen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Dieterle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Martina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Conen.

Additional information

Conflict of interest None.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conen, D., Zeller, A., Dieterle, T. et al. C-reactive protein and echocardiography have little impact on risk stratification in never-treated hypertensive patients. J Hum Hypertens 20, 587–592 (2006). https://doi.org/10.1038/sj.jhh.1002048

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002048

Keywords

Search

Advanced search

Quick links